Jaguar Health Inc(JAGX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 5:04 AM ET (Korea 9/29 18:04)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5482.2 | Insider Own | 8.18% | Shs Outstand | 0.5M | Perf Week | 125.47% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.5M | Perf Month | -53.6% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 0.07% | Short Float | 4.73% | Perf Quarter | -86.44% |
| Income | -0.05B | P/S | 0.11 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.02 | Perf Half Y | -96.65% |
| Sales | 0.03B | P/B | 0.29 | EPS next 5Y | - | ROA | -88.27% | Short Interest | 0.02M | Perf YTD | -98.77% |
| Book/sh | 20.43 | P/C | 0.47 | EPS past 3/5Y | 92.49% 85.33% | ROE | -498.47% | 52W High | -99.53% ($1280.95) | Perf Year | -99.47% |
| Cash/sh | 12.69 | P/FCF | - | Sales past 3/5Y | -1.26% 4.17% | ROIC | -395.01% | 52W Low | 156.17% ($2.35) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 85.5% | Gross Margin | 75% | Volatility(W/M) | 334.06% 96.63% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | 0.47 | Sales Y/Y TTM | 135.52% | Oper. Margin | -90.22% | ATR (14) | 5.22 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 0.4 | EPS Q/Q | 95.63% | Profit Margin | -188.46% | RSI (14) | 46.16 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.69 | Sales Q/Q | -58.88% | SMA20 | -23.93% ($7.91) | Beta | -0.16 | Target Price | $3937.5 |
| Payout | - | Debt/Eq | 2.76 | Earnings | 2026/8/19 | SMA50 | -49% ($11.8) | Rel Volume | 1.23 | Prev Close | $7.7 |
| Employees | 47 | LT Debt/Eq | 0.39 | EPS/Sales Surpr. | - | SMA200 | -96.8% ($188.12) | Avg Volume(3M) | 1.15M | Price | $6.02 |
| IPO | 2015/5/13 | Option/Short | No/Yes | Trades | 9373 | Volume | 1,413,281 | Change | -21.82% |
Jaguar Health () is a US-listed micro-cap pharmaceutical company that develops and sells gastrointestinal (GI) treatments based on the plant-derived compound Crofelemer. Its portfolio includes Mytesi for humans and Canalevia for companion animals, and the company has recently licensed out its US rights and is reshaping its business around the rare disease area of intestinal failure.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded about as much as usual That is 123% of its average volume.
JAGX has weak earnings and a weak balance sheet
Of every $100 in sales, $90.22 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $11. Peers typically go for $1,227.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.1%.
Tap to view numbers
It ranks #570 of 592 in the industry
Based on market cap of $3M.
FAQ
What kind of company is JAGX?
JAGX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of JAGX?
The market cap of JAGX is approximately $3M, ranking 5,780 within its sector.
What is the 52-week high and low for JAGX?
JAGX has recorded a 52-week high of $1280.95 and a low of $2.35.
